| Name | Title | Contact Details |
|---|
TAG Restaurant Group (TRG) is a Denver-based restaurant collection founded by Chef Troy Guard. Beginning in 2009 with a continentally-charged restaurant located on Denvers historic Larimer Square, TRG has evolved into a culinary powerhouse, garnering local and national attention as well as many accolades along the way. TRG currently operates four concepts over eleven locations in the Denver metro area, and Houston: Los Chingones (four locations), Guard and Grace Denver and Houston, Bubu (three locations), and HashTAG (est. 2017). TAG Restaurant Group strives to shake up your typical dining by offering immersive culinary experiences deeply rooted in and inspired by Chef Troys life and travels. They are crafted with genuine hospitality in mind and are never shy to produce bold, worldly flavors using local ingredients. More than the sum of their parts, TRGs brands represent a way of life and a celebration of the unexpected. The feeling of an Ohana (Hawaiian word for Family) passionately pursuing culinary excellence is tangible. Here, stories are made, told, and remembered. We operate under one vision. The TAG Restaurant Group is a celebration of the unexpected! We will deliver our guests an inspiring vibe with a memorable experience. Our intense focus will be on impeccable service. We will go above and beyond to pursue culinary excellence and grow the TAG Restaurant Group with our OHANA. Our staff exemplifies our core values: Passion, Imagination, Caring, Courage, Harmony, Humility, and Ownership. We look forward to serving you soon, Bon Appetit!
DESTINATION DEVELOPMENT Understanding what exists in your destination is important. Knowledge of your cannabis and hemp-related assets directly informs the strategy and program architecture. I engage and educate stakeholders, assess the destination, and develop a bespoke cannabis travel strategy and program that fosters long term success. The strategy may or may not include B2C product development i.e. trail, passport, newsletter. DESTINATION MARKETING The data shows that the cannabis-motivated active leisure travel audience is a high value audience that stays longer and spends more while in a destination. Through a dedicated cannabis travel program, I work with stakeholders to facilitate a steady flow of cannabis and hemp-related content that elevates the cannabis experience story in a sophisticated and brand aligned way. I advise DMOs on B2B and B2C content and marketing strategies. HOTEL SOLUTIONS Hotels are the heart of the travel ecosystem of a destination. Hotels greatly influence the overall experience for visitors. With a focus on guest experience, room nights, and turn-key incremental revenue opportunities, I help hotels understand, prepare for, and serve the cannabis and hemp CBD-interested hotel guest. Solutions include hospitality education, frontline staff support, and revenue generating opportunities in lobby, spa, and in-room.
Miller Engineerings design and consulting team provides over 100 cumulative years of construction and design experience, which will ensure the success of your project.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.